<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: early stage", fill: "#f88379"},
{source: "1: early stage", target: "1: drug discovery", fill: "#f88379"},
{source: "1: drug discovery", target: "1: development efforts", fill: "#f88379"},
{source: "1: development efforts", target: "1: unsuccessful", fill: "#f88379"},
{source: "1: early stage", target: "2: early stage", fill: "#ffddf4"},
{source: "2: early stage", target: "2: drug discovery", fill: "#ffddf4"},
{source: "2: drug discovery", target: "2: development", fill: "#ffddf4"},
{source: "2: development", target: "2: operations", fill: "#ffddf4"},
{source: "2: early stage", target: "3: commercialize", fill: "#ff6fff"},
{source: "3: commercialize", target: "3: pharmaceutical products will depend on", fill: "#ff6fff"},
{source: "3: pharmaceutical products will depend on", target: "3: key scientific employees", fill: "#ff6fff"},
{source: "3: key scientific employees", target: "3: high quality therapeutic targets", fill: "#ff6fff"},
{source: "3: high quality therapeutic targets", target: "3: potential drug candidates", fill: "#ff6fff"},
{source: "3: potential drug candidates", target: "3: products internally", fill: "#ff6fff"},
{source: "3: products internally", target: "3: enroll suitable human subjects either", fill: "#ff6fff"},
{source: "3: enroll suitable human subjects either", target: "3: laboratory", fill: "#ff6fff"},
{source: "3: laboratory", target: "3: necessary", fill: "#ff6fff"},
{source: "3: necessary", target: "3: intellectual", fill: "#ff6fff"},
{source: "3: intellectual", target: "3: regulatory", fill: "#ff6fff"},
{source: "3: regulatory", target: "3: in the United States ", fill: "#ff6fff"},
{source: "3: in the United States ", target: "3: arrangements", fill: "#ff6fff"},
{source: "3: arrangements", target: "3: third parties", fill: "#ff6fff"},
{source: "3: third parties", target: "3: manufacture", fill: "#ff6fff"},
{source: "3: manufacture", target: "3: products on", fill: "#ff6fff"},
{source: "3: products on", target: "3: efficient production", fill: "#ff6fff"},
{source: "3: efficient production", target: "3: facilities meeting", fill: "#ff6fff"},
{source: "3: facilities meeting", target: "3: regulatory requirements", fill: "#ff6fff"},
{source: "3: regulatory requirements", target: "3: deploy sales", fill: "#ff6fff"},
{source: "3: deploy sales", target: "3: marketing resources effectively", fill: "#ff6fff"},
{source: "3: marketing resources effectively", target: "3: lease facilities at reasonable rates", fill: "#ff6fff"},
{source: "3: commercialize", target: "14: discovery", fill: "#008000"},
{source: "14: discovery", target: "14: suitable drug candidate", fill: "#008000"},
{source: "14: suitable drug candidate", target: "14: clinical pipeline", fill: "#008000"},
{source: "14: clinical pipeline", target: "14: enter into agreements with collaborators", fill: "#008000"},
{source: "14: enter into agreements with collaborators", target: "14: drug candidates", fill: "#008000"},
{source: "14: discovery", target: "16: establish collaborations", fill: "#6050dc"},
{source: "16: establish collaborations", target: "16: future collaborations", fill: "#6050dc"},
{source: "16: future collaborations", target: "16: unsuccessful", fill: "#6050dc"},
{source: "16: unsuccessful", target: "16: development efforts may", fill: "#6050dc"},
{source: "16: development efforts may", target: "16: adversely affect", fill: "#6050dc"},
{source: "16: adversely affect", target: "16: operations", fill: "#6050dc"},
{source: "16: establish collaborations", target: "17: strategy will", fill: "#9400d3"},
{source: "17: strategy will", target: "17: enter into", fill: "#9400d3"},
{source: "17: enter into", target: "17: collaborative", fill: "#9400d3"},
{source: "17: collaborative", target: "17: parties such as", fill: "#9400d3"},
{source: "17: parties such as", target: "17: collaboration with", fill: "#9400d3"},
{source: "17: collaboration with", target: "17: drug candidates", fill: "#9400d3"},
{source: "17: drug candidates", target: "17: development", fill: "#9400d3"},
{source: "17: development", target: "17: commercialization", fill: "#9400d3"},
{source: "17: strategy will", target: "18: initial clinical trials on", fill: "#8f00ff"},
{source: "18: initial clinical trials on", target: "18: candidates", fill: "#8f00ff"},
{source: "18: candidates", target: "18: seek collaborators", fill: "#8f00ff"},
{source: "18: seek collaborators", target: "18: candidates such as", fill: "#8f00ff"},
{source: "18: candidates such as", target: "18: chemokine receptor antagonists", fill: "#8f00ff"},
{source: "18: chemokine receptor antagonists", target: "18: expense effort", fill: "#8f00ff"},
{source: "18: expense effort", target: "18: continue additional clinical", fill: "#8f00ff"},
{source: "18: continue additional clinical", target: "18: drug candidates", fill: "#8f00ff"},
{source: "18: initial clinical trials on", target: "26: collaborators", fill: "#e97451"},
{source: "26: collaborators", target: "26: potential products", fill: "#e97451"},
{source: "26: collaborators", target: "START_HERE", fill: "#e97451"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_discovery">Drug discovery</a></td>
      <td>In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_studies">Development studies</a></td>
      <td>Development studies is an interdisciplinary branch of social science. Development studies is offered as a specialized master's degree in a number of reputed universities around the world, such as the University of Cambridge, the London School of Economics and Political Science, King’s College London, the Institute of Development Studies at the University of Sussex, Oxford University, Harvard University, Balsillie School of International Affairs, Graduate Institute Geneva, Indian Institute of Technology Madras, SOAS London, Tata Institute of Social Sciences and University of Warwick, and less commonly, as an undergraduate degree, such as at the University of Sussex, University of Guelph, University of Toronto and McGill University.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_Development_Index">Human Development Index</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Notepad">Windows Notepad</a></td>
      <td>Windows Notepad is a simple text editor for Windows; it creates and edits plain text documents. First released in 1983 to commercialize the computer mouse in MS-DOS, Notepad has been part of every version of Windows ever since.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bleiburg_repatriations">Bleiburg repatriations</a></td>
      <td>In May 1945, after the end of World War II in Europe, during which Yugoslavia had been occupied by the Axis powers, tens of thousands of soldiers and civilians associated with the Axis powers fled Yugoslavia to Austria as the Soviet Union (Red Army) and Yugoslav Partisans took control. When they reached Allied-occupied Austria, the British refused to accept their surrender and directed them to the Partisans instead despite knowing that they would be killed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_frequent_David_Lynch_collaborators">List of frequent David Lynch collaborators</a></td>
      <td>David Keith Lynch (born January 20, 1946) is an American filmmaker, painter, television director, visual artist, musician, and occasional actor. Known for his surrealist films, he has developed his own unique cinematic style, known as "Lynchian"; this style is characterized by its dream imagery and meticulous sound design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chinilpa">Chinilpa</a></td>
      <td>Chinilpa (Korean: 친일파, lit. "pro-Japan faction") is a derogatory Korean language term that denotes ethnic Koreans who collaborated with Imperial Japan during the protectorate period of the Korean Empire from 1905 and its colonial rule in Korea from 1910 to 1945.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>INCYTE CORP      Item 1A Risk Factors       RISKS RELATING TO OUR BUSINESS       We are at the <font color="blue">early stage</font> of our <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue"><font color="blue">development</font> efforts</font> and     we may be <font color="blue">unsuccessful</font> in our efforts</td>
    </tr>
    <tr>
      <td>We are in the <font color="blue">early stage</font> of building our <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font>     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  ability  to  discover,  develop,  and  <font color="blue">commercialize</font>     <font color="blue"><font color="blue">pharmaceutical</font> products will <font color="blue">depend on</font></font> our ability to:       ·       hire and retain <font color="blue">key scientific employees</font>;       ·       identify <font color="blue">high quality therapeutic targets</font>;       ·       identify <font color="blue">potential drug <font color="blue">candidates</font></font>;       ·       develop <font color="blue">products internally</font> or <font color="blue">license drug</font> <font color="blue">candidates</font> from others;       ·       identify and enroll suitable human subjects, either in the United     States or abroad, for our <font color="blue"><font color="blue">clinical trial</font>s</font>;       ·       complete <font color="blue">laboratory</font> testing and <font color="blue"><font color="blue">clinical trial</font>s</font> on humans;       ·       obtain and maintain <font color="blue">necessary</font> <font color="blue">intellectual</font> property rights to our     products;       ·       obtain and maintain <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals for our products,     both <font color="blue">in the <font color="blue">United States </font></font>and abroad;       ·       <font color="blue">enter into</font> <font color="blue">arrangements</font> with <font color="blue">third parties</font> to provide services or to     <font color="blue">manufacture</font> our <font color="blue">products on</font> our behalf, or develop <font color="blue">efficient production</font>     <font color="blue"><font color="blue">facilities</font> meeting</font> all <font color="blue">regulatory</font> <font color="blue">requirements</font>;       ·       <font color="blue">deploy sales</font> and <font color="blue">marketing resources <font color="blue">effective</font>ly</font> or <font color="blue">enter into</font>     <font color="blue">arrangements</font> with <font color="blue">third parties</font> to provide these functions;       ·       <font color="blue">lease <font color="blue">facilities</font> at reasonable rates</font> to support our growth; and       ·        enter  into  <font color="blue">arrangements</font>  with  <font color="blue">third parties</font> to license and     <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Of the compounds that we identify as potential <font color="blue"><font color="blue">drug product</font>s</font> or that we     in-license from other companies, only a few, at most, are <font color="blue">statistically</font>     likely to lead to successful drug <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>research     and <font color="blue"><font color="blue">development</font> efforts</font> will be <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>We have limited experience with     these <font color="blue">activities</font> and may not be successful in <font color="blue">discovering</font>, developing, or     <font color="blue"><font color="blue">commercializing</font> <font color="blue"><font color="blue">drug product</font>s</font></font></td>
    </tr>
    <tr>
      <td>If we choose to outsource some of these     <font color="blue">activities</font>,  we  may  be unable to <font color="blue"><font color="blue">enter into</font> outsourcing</font> or licensing     <font color="blue"><font color="blue">agreement</font>s on commercially reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>In addition, if we     elect to <font color="blue">manufacture</font> our products in our own <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font>, we     will require substantial <font color="blue"><font color="blue">additional</font> capital resources</font> to lease or build and     maintain those <font color="blue">facilities</font>, including attracting and retaining qualified     personnel to lease or build and operate our <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Our efforts to discover and develop <font color="blue">potential drug <font color="blue">candidates</font></font> may not lead     to  the <font color="blue">discovery</font>, <font color="blue">development</font>, <font color="blue">commercialization</font> or marketing of drug     products</td>
    </tr>
    <tr>
      <td>We are currently engaged in a number of <font color="blue">different approaches</font> to discover and     develop <font color="blue">novel drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>At the present time, we have three drug     <font color="blue">candidates</font>, DFC, our lead CCR2 <font color="blue">antagonist licensed</font> to Pfizer, and our lead     sheddase  inhibitor in Phase IIb, Phase IIa, and Phase Ib/IIa clinical     trials, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Our other internal <font color="blue">drug <font color="blue">discovery</font></font> programs are focused     on compounds with potential for <font color="blue"><font color="blue">application</font>s</font> in HIV, diabetes and cancer</td>
    </tr>
    <tr>
      <td><font color="blue">Discovery </font>and <font color="blue">development</font> of <font color="blue">potential drug <font color="blue">candidates</font></font> are expensive and     time-consuming, and we do not know if our efforts will lead to <font color="blue">discovery</font> of     any drug <font color="blue">candidates</font> that can be <font color="blue">successfully</font> developed and marketed</td>
    </tr>
    <tr>
      <td>If our     efforts do not lead to the <font color="blue">discovery</font> of a       15     ______________________________________________________________________       <font color="blue">suitable drug candidate</font>, we may be unable to grow our <font color="blue">clinical pipeline</font> or     we may be unable to <font color="blue"><font color="blue">enter into</font> <font color="blue">agreement</font>s with <font color="blue"><font color="blue">collaborator</font>s</font></font> who are willing     to develop our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>The success of our <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue"><font color="blue">development</font> efforts</font> may <font color="blue">depend on</font> our     ability to <font color="blue">find suitable <font color="blue"><font color="blue">collaborator</font>s</font></font> to <font color="blue">fully exploit</font> our <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>If     we are unable to <font color="blue">establish <font color="blue">collaboration</font>s</font> or if these <font color="blue">future <font color="blue">collaboration</font>s</font>     are <font color="blue">unsuccessful</font>, our research and <font color="blue"><font color="blue">development</font> efforts</font> may be <font color="blue">unsuccessful</font>,     which  could  <font color="blue"><font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>An  important  element  of our business <font color="blue">strategy will</font> be to <font color="blue">enter into</font>     <font color="blue">collaborative</font>  or license <font color="blue">arrangements</font> with other parties, such as our     <font color="blue"><font color="blue">collaboration</font> with</font> Pfizer, under which we license our drug <font color="blue">candidates</font> to     those parties for <font color="blue">development</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We expect that while we     may  initially  seek  to  conduct  <font color="blue">initial <font color="blue"><font color="blue">clinical trial</font>s</font> on</font> our drug     <font color="blue">candidates</font>, we will need to <font color="blue">seek <font color="blue"><font color="blue">collaborator</font>s</font></font> for a number of our drug     <font color="blue">candidates</font>, such as our <font color="blue">chemokine receptor <font color="blue">antagonists</font></font>, because of the     expense, effort and expertise required to <font color="blue">continue <font color="blue">additional</font> clinical</font>     trials and further develop those drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">collaboration</font>     <font color="blue">arrangements</font> are complex to negotiate, we may not be successful in our     attempts  to  establish these <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Also, we may not have drug     compounds that are desirable to other parties, or we may be unwilling to     license a <font color="blue">drug compound</font> because the <font color="blue">party interested</font> in it is a <font color="blue">competitor</font></td>
    </tr>
    <tr>
      <td>The terms of any such <font color="blue">arrangements</font> that we <font color="blue">establish may</font> not be favorable to     us</td>
    </tr>
    <tr>
      <td>Alternatively, <font color="blue">potential <font color="blue"><font color="blue">collaborator</font>s</font></font> may decide against entering into     an <font color="blue"><font color="blue">agreement</font> with us</font> because of our financial, <font color="blue">regulatory</font> or <font color="blue">intellectual</font>     <font color="blue">property position</font> or for scientific, commercial or other reasons</td>
    </tr>
    <tr>
      <td>If we are     not  able to establish <font color="blue">collaborative</font> <font color="blue">agreement</font>s, we may not be able to     develop and <font color="blue">commercialize</font> a <font color="blue">drug product</font>, which would <font color="blue"><font color="blue">adversely</font> affect</font> our     business and our revenues</td>
    </tr>
    <tr>
      <td>In  order for any of these <font color="blue">collaboration</font> or license <font color="blue">arrangements</font> to be     successful, we must first identify <font color="blue">potential <font color="blue"><font color="blue">collaborator</font>s</font></font> or licensees     whose <font color="blue">capabilities</font> <font color="blue">complement</font> and <font color="blue">integrate well with ours</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may rely on</font>     these <font color="blue">arrangements</font> for not only financial resources, but also for expertise     or economies of scale that we expect to need in the future relating to     <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">manufacturing</font>, sales and marketing, and for licenses to     <font color="blue"><font color="blue">technology</font> rights</font></td>
    </tr>
    <tr>
      <td>However, it is likely that we will not be able to control     the amount and timing of resources that our <font color="blue"><font color="blue">collaborator</font>s</font> or licensees     devote  to our programs or <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">collaborator</font>s</font> or     <font color="blue">licensees prove <font color="blue">difficult</font></font> to work with, are <font color="blue">less skilled than</font> we <font color="blue">originally</font>     expected  or  do  not  devote  adequate  resources to the program, the     <font color="blue"><font color="blue">relationship</font> will</font> not be successful</td>
    </tr>
    <tr>
      <td>If a business <font color="blue">combination</font> involving a     <font color="blue">collaborator</font> or licensees and a <font color="blue">third party</font> were to occur, the effect could     be to diminish, terminate or cause delays in <font color="blue">development</font> of a potential     product</td>
    </tr>
    <tr>
      <td>We <font color="blue">face <font color="blue">significant</font> competition</font> for our <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font>     efforts, and if we do not <font color="blue">compete <font color="blue">effective</font>ly</font>, our <font color="blue">commercial opportunities</font>     will be reduced or eliminated</td>
    </tr>
    <tr>
      <td>The <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue"><font color="blue">pharmaceutical</font> industries</font> are <font color="blue">intensely competitive</font>     and  subject  to  rapid and <font color="blue"><font color="blue">significant</font> technological</font> change</td>
    </tr>
    <tr>
      <td>Our drug     <font color="blue">discovery</font> and <font color="blue"><font color="blue">development</font> efforts</font> may target diseases and <font color="blue">conditions</font> that     are already subject to <font color="blue">existing therapies</font> or that are being developed by our     <font color="blue">competitor</font>s, many of which have <font color="blue">substantially</font> greater resources, larger     research  and  <font color="blue">development</font>  staffs  and <font color="blue">facilities</font>, more experience in     completing  <font color="blue"><font color="blue">preclinical test</font>ing</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> in order to obtain     <font color="blue">regulatory</font>  approvals  and  <font color="blue">formulation</font>,  marketing  and <font color="blue">manufacturing</font>     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>As a result of these resources, our <font color="blue">competitor</font>s may develop     drug  products  that render our products obsolete or <font color="blue">noncompetitive</font> by     developing  more  <font color="blue">effective</font> drugs or by developing their products more     <font color="blue">efficiently</font></td>
    </tr>
    <tr>
      <td>Our ability to develop <font color="blue">competitive products would</font> be limited if     our  <font color="blue">competitor</font>s  succeeded in obtaining <font color="blue">regulatory</font> approvals for drug     <font color="blue">candidates</font>  more  rapidly  than we were able to or in obtaining patent     protection or other <font color="blue">intellectual</font> property rights that limited our drug     <font color="blue"><font color="blue">development</font> efforts</font></td>
    </tr>
    <tr>
      <td>Any drugs resulting from our research and <font color="blue">development</font>     efforts, or from our joint efforts with <font color="blue"><font color="blue">collaborator</font>s</font> or licensees, might     not be able to compete <font color="blue">successfully</font> with our <font color="blue">competitor</font>s’ existing and     <font color="blue">future products</font>, or obtain <font color="blue">regulatory</font> approval <font color="blue">in the <font color="blue">United States </font></font>or     elsewhere</td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       Our ability to develop and <font color="blue">commercialize</font> DFC may be <font color="blue"><font color="blue">adversely</font> affect</font>ed if a     dispute arose with <font color="blue">Pharmasset </font>or between <font color="blue">Pharmasset </font>and its licensor Emory     University</td>
    </tr>
    <tr>
      <td>We  are  developing DFC under a <font color="blue">collaborative</font> licensing <font color="blue">agreement</font> with     <font color="blue">Pharmasset </font><font color="blue">entered into</font> in <font color="blue">September </font>2003 under which <font color="blue">Pharmasset </font><font color="blue">exclusively</font>     sublicensed to <font color="blue">us <font color="blue">certain rights</font></font> in DFC, including certain of its analogs     and <font color="blue">derivatives</font> that were developed by <font color="blue">Pharmasset </font>or that were in-licensed     by <font color="blue">Pharmasset </font>from Emory</td>
    </tr>
    <tr>
      <td>If a dispute arose with <font color="blue">Pharmasset </font>over the terms     of the <font color="blue">collaborative</font> license <font color="blue">agreement</font> or a dispute arose between <font color="blue">Pharmasset </font>    and Emory over the terms of the <font color="blue">license <font color="blue">agreement</font> between them</font>, including     the alleged breach of any provision, our <font color="blue">development</font>, <font color="blue">commercialization</font> and     marketing of DFC may be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmasset </font>has the right to     terminate the <font color="blue">agreement</font> if we do not <font color="blue">use commercially reasonable efforts</font> to     develop or <font color="blue">commercialize</font> DFC in our <font color="blue">territories</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">Pharmasset </font>terminates     the <font color="blue">agreement</font> for cause, or if we terminate the <font color="blue">agreement</font> without cause, all     licenses to us under the <font color="blue">agreement</font> terminate</td>
    </tr>
    <tr>
      <td>We  depend  on  our  <font color="blue"><font color="blue">collaboration</font> with</font> Pfizer for the <font color="blue">development</font> and     <font color="blue">commercialization</font> of CCR2 <font color="blue">antagonist compounds</font></td>
    </tr>
    <tr>
      <td>Under our <font color="blue">collaborative</font> research and license <font color="blue">agreement</font> with Pfizer, Pfizer     gained worldwide <font color="blue">development</font> and <font color="blue">commercialization</font> rights to our portfolio     of CCR2 <font color="blue">antagonist compounds</font></td>
    </tr>
    <tr>
      <td>Pfizer’s <font color="blue">rights extend</font> to the full scope of     potential <font color="blue">indications</font>, with the exception of <font color="blue">multiple sclerosis</font> and one     other <font color="blue">undisclosed indication</font></td>
    </tr>
    <tr>
      <td>Although  Pfizer is required to <font color="blue">use commercially reasonable efforts</font> to     develop and <font color="blue">commercialize</font> CCR2 <font color="blue">antagonists</font> for the <font color="blue">indications</font> for which     they are responsible, we <font color="blue">cannot control</font> the amount and timing of resources     Pfizer may devote to the <font color="blue">development</font> of CCR2 <font color="blue">antagonists</font></td>
    </tr>
    <tr>
      <td>Any failure of     Pfizer to perform its <font color="blue">obligations</font> under our <font color="blue">agreement</font> could <font color="blue">negatively</font>     impact the <font color="blue">development</font> of CCR2 <font color="blue">antagonists</font>, lead to our loss of potential     <font color="blue">revenues from product sales</font> and <font color="blue">milestones</font> and delay our <font color="blue">achievement</font>, if     any, of <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Pfizer has <font color="blue">certain rights</font> to terminate the license <font color="blue">agreement</font>, including the     right to terminate upon 90 days’ notice for any reason</td>
    </tr>
    <tr>
      <td>Pfizer also has the     right  to terminate its rights and <font color="blue">obligations</font> with respect to certain     <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>If Pfizer terminates the license <font color="blue">agreement</font> or its <font color="blue">rights with</font>     respect  to  certain  <font color="blue">indications</font>,  we  may  not be able to find a new     <font color="blue">collaborator</font>  to  replace  Pfizer, and our business could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>If  conflicts arise between our <font color="blue"><font color="blue">collaborator</font>s</font> including <font color="blue">Pharmasset </font>and     Pfizer, licensees, or advisors and us, our <font color="blue"><font color="blue">collaborator</font>s</font>, licensees, or     <font color="blue">advisors may</font> act in their self-interest, which may <font color="blue"><font color="blue">adversely</font> affect</font> our     business</td>
    </tr>
    <tr>
      <td>If conflicts arise <font color="blue">between us</font> and our <font color="blue"><font color="blue">collaborator</font>s</font> or licensees, including     <font color="blue">Pharmasset </font>and Pfizer, or our scientific advisors, the other party may act     in its self-interest and not in the interest of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Conflicts     </font>may arise with our <font color="blue"><font color="blue">collaborator</font>s</font> or licensees if they <font color="blue">pursue alternative</font>     <font color="blue">technologies</font> or develop <font color="blue">alternative <font color="blue">products either</font> on</font> their own or in     <font color="blue"><font color="blue">collaboration</font> with</font> others as a means for developing <font color="blue">treatments</font> for the     diseases that we have targeted</td>
    </tr>
    <tr>
      <td><font color="blue">Competing </font>products, either developed by     these  future  <font color="blue"><font color="blue">collaborator</font>s</font>  or  licensees  or  to which these future     <font color="blue"><font color="blue">collaborator</font>s</font> or licensees have rights, may result in their withdrawal of     support for our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Additionally,  conflicts  may  arise  if  there is a <font color="blue">dispute about</font> the     <font color="blue">achievement</font>  and  payment  of  a  <font color="blue">milestone amount</font> or the ownership of     <font color="blue">intellectual</font>  property  that  is  developed  during  the course of the     <font color="blue">relationship</font></td>
    </tr>
    <tr>
      <td>Similarly, the parties to a <font color="blue">collaboration</font> or license <font color="blue">agreement</font>     <font color="blue">may disagree as</font> to <font color="blue">which party</font> owns newly developed products</td>
    </tr>
    <tr>
      <td>Should an     <font color="blue">agreement</font> be terminated as a result of a dispute and before we have realized     the benefits of the <font color="blue">collaboration</font> or license, our <font color="blue">reputation could</font> be harmed     and we may not obtain revenues that we anticipated receiving</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________       If  we  fail to <font color="blue">enter into</font> <font color="blue">additional</font> licensing <font color="blue">agreement</font>s or if these     <font color="blue">arrangements</font>  are  <font color="blue">unsuccessful</font>,  our business and <font color="blue">operations</font> might be     <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">establishing</font> <font color="blue">collaborative</font> or license <font color="blue">arrangements</font> under     which  other  parties  license our drug <font color="blue">candidates</font> for <font color="blue">development</font> and     <font color="blue">commercialization</font>, we intend to continue to <font color="blue">explore opportunities</font> to develop     our <font color="blue">clinical pipeline</font> by in-licensing <font color="blue">drug compound</font>s that fit within our     expertise and research and <font color="blue">development</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We may be unable to     <font color="blue">enter into</font> any <font color="blue">additional</font> in-licensing <font color="blue">agreement</font>s because <font color="blue">suitable product</font>     <font color="blue">candidates</font> that are within our <font color="blue">expertise may</font> not be available to us on terms     that are acceptable to us or because <font color="blue">competitor</font>s with greater resources seek     to in-license the same product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">candidates</font> that we would     like to develop may not be available to us because they are <font color="blue">controlled by</font>     <font color="blue">competitor</font>s who are unwilling to license the rights to the <font color="blue">drug compound</font> or     candidate  to  us</td>
    </tr>
    <tr>
      <td>We may also need to <font color="blue"><font color="blue">license drug</font> delivery</font> or other     <font color="blue">technology</font> in order to continue to develop our <font color="blue">drug candidate pipeline</font></td>
    </tr>
    <tr>
      <td>If     we  are  unable  to  enter  into <font color="blue">additional</font> <font color="blue">agreement</font>s to <font color="blue">license drug</font>     <font color="blue">candidates</font>,  drug  delivery <font color="blue">technology</font> or other <font color="blue">technology</font> or if these     <font color="blue">arrangements</font> are <font color="blue">unsuccessful</font>, our research and <font color="blue"><font color="blue">development</font> efforts</font> could be     <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">expertise with</font> and <font color="blue">capacity</font> to conduct <font color="blue"><font color="blue">preclinical test</font>ing</font>     and <font color="blue"><font color="blue">clinical trial</font>s</font>, and our resulting <font color="blue">dependence on</font> other <font color="blue">parties could</font>     result in delays in and <font color="blue"><font color="blue">additional</font> costs</font> for our drug <font color="blue"><font color="blue">development</font> efforts</font></td>
    </tr>
    <tr>
      <td>We  have  only  limited  experience with <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">formulation</font>,     <font color="blue">manufacturing</font> and <font color="blue">commercialization</font> of <font color="blue"><font color="blue">drug product</font>s</font></td>
    </tr>
    <tr>
      <td>We also have limited     <font color="blue">internal resources</font> and <font color="blue">capacity</font> to perform <font color="blue"><font color="blue">preclinical test</font>ing</font> and clinical     trials</td>
    </tr>
    <tr>
      <td>As a result, we intend to hire Clinical Research Organizations     (“CROs”)  to  perform <font color="blue"><font color="blue">preclinical test</font>ing</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> for drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the CROs </font>that we hire to perform our <font color="blue"><font color="blue">preclinical test</font>ing</font> and     <font color="blue"><font color="blue">clinical trial</font>s</font> or our <font color="blue"><font color="blue">collaborator</font>s</font> or licensees do not <font color="blue">meet deadlines</font>, do     not follow proper procedures, or a conflict arises <font color="blue">between us</font> and our CROs,     our <font color="blue"><font color="blue">preclinical test</font>ing</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> may take <font color="blue">longer than</font> expected,     may be delayed or may be terminated</td>
    </tr>
    <tr>
      <td>If we were forced to find a <font color="blue">replacement</font>     entity to perform any of our <font color="blue"><font color="blue">preclinical test</font>ing</font> or <font color="blue"><font color="blue">clinical trial</font>s</font>, we may     not be able to find a suitable entity on favorable terms, or at all</td>
    </tr>
    <tr>
      <td>Even if     we  were able to find another company to perform a <font color="blue">preclinical test</font> or     <font color="blue">clinical trial</font>, the delay in the test or trial may result in <font color="blue">significant</font>     <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>Events such as these may result in delays in our obtaining     <font color="blue">regulatory</font> approval for our drug <font color="blue">candidates</font> or our ability to <font color="blue">commercialize</font>     our products and could result in increased <font color="blue">expenditures</font> that would <font color="blue">adversely</font>     affect our operating results</td>
    </tr>
    <tr>
      <td>In addition, for some of our drug <font color="blue">candidates</font>, we plan to <font color="blue">contract with</font>     <font color="blue"><font color="blue">collaborator</font>s</font> or licensees to advance those <font color="blue">candidates</font> through later-stage,     more expensive <font color="blue"><font color="blue">clinical trial</font>s</font>, rather than invest our own resources to     perform these <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>on the terms of our <font color="blue">agreement</font>s with     these <font color="blue"><font color="blue">collaborator</font>s</font> or licensees, we may not have any <font color="blue">control over</font> the     conduct of these <font color="blue"><font color="blue">clinical trial</font>s</font>, and in any event we would be subject to     the <font color="blue">risks <font color="blue">associated with</font></font> depending on <font color="blue"><font color="blue">collaborator</font>s</font> or licensees to develop     these drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If  we  are unable to obtain <font color="blue">regulatory</font> approval to develop and market     products <font color="blue">in the <font color="blue">United States </font></font>and foreign <font color="blue">jurisdictions</font>, we will not be     permitted  to <font color="blue">manufacture</font> or <font color="blue">commercialize</font> products resulting from our     research</td>
    </tr>
    <tr>
      <td>In  order to <font color="blue">manufacture</font> and <font color="blue">commercialize</font> <font color="blue"><font color="blue">drug product</font>s</font> in the United     States, our drug <font color="blue">candidates</font> will have to obtain <font color="blue">regulatory</font> approval from the     Food  and  Drug Administration, or the FDA Satisfaction of <font color="blue">regulatory</font>     <font color="blue">requirements</font> typically takes many years</td>
    </tr>
    <tr>
      <td>To obtain <font color="blue">regulatory</font> approval, we     <font color="blue">must first show</font> that our <font color="blue"><font color="blue">drug product</font>s</font> are safe and <font color="blue">effective</font> for target     <font color="blue">indications</font> through <font color="blue"><font color="blue">preclinical test</font>ing</font> (animal testing) and <font color="blue"><font color="blue">clinical trial</font>s</font>     (<font color="blue">human testing</font>)</td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>testing and clinical <font color="blue">development</font> are long,     expensive and <font color="blue">uncertain processes</font>, and we do not know whether the FDA will     allow us to undertake <font color="blue"><font color="blue">clinical trial</font>s</font> of any potential <font color="blue"><font color="blue">drug product</font>s</font> in     addition to our <font color="blue">compounds currently</font> in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       <font color="blue">Completion </font>of <font color="blue"><font color="blue">clinical trial</font>s</font> may take <font color="blue">several years</font> and failure may occur     at any stage of testing</td>
    </tr>
    <tr>
      <td>The length of time required <font color="blue">varies <font color="blue">substantially</font></font>     <font color="blue">according</font> to the type, complexity, novelty and <font color="blue">intended use</font> of the product     candidate</td>
    </tr>
    <tr>
      <td>Interim results of a <font color="blue">preclinical test</font> or <font color="blue">clinical trial</font> do not     <font color="blue">necessarily predict final</font> results, and acceptable results in <font color="blue">early clinical</font>     <font color="blue">trials may</font> not be repeated in later <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>For example, a drug     candidate that is <font color="blue">successful at</font> the <font color="blue">pre<font color="blue">clinical level</font> may</font> cause harmful or     <font color="blue">dangerous</font>  side effects when tested at the <font color="blue">clinical level</font></td>
    </tr>
    <tr>
      <td>Our rate of     <font color="blue">commencement</font>  and <font color="blue">completion</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> may be <font color="blue">delayed by</font> many     factors, including:       ·       the high degree of risk <font color="blue">associated with</font> drug <font color="blue">development</font>;       ·       our <font color="blue">inability</font> to formulate or <font color="blue">manufacture</font> <font color="blue">sufficient quantities</font> of     materials for use in <font color="blue"><font color="blue">clinical trial</font>s</font>;       ·       <font color="blue">variability</font> in the number and types of <font color="blue">patients available</font> for each     study;       ·       <font color="blue"><font color="blue">difficult</font>y</font> in maintaining <font color="blue">contact with patients</font> after treatment,     resulting in <font color="blue">incomplete data</font>;       ·       <font color="blue">unforeseen safety issues</font> or side effects;       ·       poor or unanticipated <font color="blue">effective</font>ness of <font color="blue">products during</font> the clinical     trials; or       ·       <font color="blue">government</font> or <font color="blue">regulatory</font> delays</td>
    </tr>
    <tr>
      <td>Data  obtained  from  the  clinical  trials are susceptible to varying     interpretation, which may delay, limit or prevent <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>A     number of companies in the <font color="blue"><font color="blue">pharmaceutical</font> industry</font>, including <font color="blue">bio<font color="blue">technology</font></font>     companies, have suffered <font color="blue">significant</font> setbacks in advanced <font color="blue"><font color="blue">clinical trial</font>s</font>,     even  after achieving promising results in earlier <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">regulatory</font> <font color="blue">authorities</font> may refuse or <font color="blue">delay approval as</font> a result of     other factors, such as changes in <font color="blue">regulatory</font> policy during the period of     product <font color="blue">development</font> and <font color="blue">regulatory</font> agency review</td>
    </tr>
    <tr>
      <td>In <font color="blue">September </font>2005, the FDA     requested  that we conduct another <font color="blue">Phase IIb </font><font color="blue">clinical trial</font> for DFC to     support the efficacy and safety <font color="blue">demonstrated</font> in the original <font color="blue">Phase IIb </font>    <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>Due,  in  part,  to the <font color="blue">early stage</font> of our <font color="blue">drug candidate research</font> and     <font color="blue">development</font> process, we <font color="blue">cannot predict whether</font> <font color="blue">regulatory</font> <font color="blue">approval will</font> be     obtained for any product we develop</td>
    </tr>
    <tr>
      <td>At the present time, we have three drug     <font color="blue">candidates</font>, DFC, our lead CCR2 <font color="blue">antagonist licensed</font> to Pfizer, and our lead     sheddase  inhibitor in Phase IIb, Phase IIa, and Phase Ib/IIa clinical     trials,  <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Our other drug <font color="blue">candidates</font> are still undergoing     <font color="blue"><font color="blue">preclinical test</font>ing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compounds </font>developed by us, alone or with other parties,     may not prove to be safe and <font color="blue">effective</font> in <font color="blue"><font color="blue">clinical trial</font>s</font> and may not meet     all of the applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> needed to receive marketing     approval</td>
    </tr>
    <tr>
      <td>If <font color="blue">regulatory</font> approval of a product is granted, this <font color="blue">approval will</font>     be limited to those disease states and <font color="blue">conditions</font> for which the product is     <font color="blue">demonstrated</font> through <font color="blue"><font color="blue">clinical trial</font>s</font> to be safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Failure to     obtain <font color="blue">regulatory</font> approval would delay or prevent us from <font color="blue">commercializing</font>     products</td>
    </tr>
    <tr>
      <td>Outside the United States, our ability to market a product is <font color="blue">contingent</font>     upon receiving a <font color="blue">marketing authorization from</font> the appropriate <font color="blue">regulatory</font>     <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>This foreign <font color="blue">regulatory</font> <font color="blue">approval process</font> typically includes all     of the <font color="blue">risks <font color="blue">associated with</font></font> the FDA <font color="blue"><font color="blue">approval process</font> described</font> above and     may also include <font color="blue"><font color="blue">additional</font> risks</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> other parties to <font color="blue">manufacture</font> our drug <font color="blue">candidates</font> could     result in a short supply of the drugs, delays in <font color="blue">development</font>, increased     costs and withdrawal or denial of the <font color="blue">regulatory</font> authority’s approval</td>
    </tr>
    <tr>
      <td>The FDA requires that <font color="blue"><font color="blue">drug product</font>s</font> be <font color="blue">manufacture</font>d <font color="blue">according</font> to its current     Good Manufacturing Practices, or cGMP, <font color="blue">regulations</font> and a limited number of     <font color="blue">manufacture</font>rs comply with these <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If the other parties that we     choose to <font color="blue">manufacture</font> our <font color="blue"><font color="blue">drug product</font>s</font> are not <font color="blue">compliant with cGMP</font>, the FDA     may not approve our <font color="blue">application</font> to <font color="blue">manufacture</font> our <font color="blue"><font color="blue">drug product</font>s</font></td>
    </tr>
    <tr>
      <td>We may not     be able to arrange for our products to be <font color="blue">manufacture</font>d by one of these     <font color="blue">parties on reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>Failure to comply with       19     ______________________________________________________________________       cGMP in the <font color="blue">manufacture</font> of our <font color="blue">products could</font> result <font color="blue">in the FDA </font>withdrawing     or denying <font color="blue">regulatory</font> approval of our <font color="blue">drug product</font> or other <font color="blue">enforcement</font>     actions</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">sufficient quantities</font> of our new <font color="blue"><font color="blue">drug product</font>s</font>     if the <font color="blue">manufacture</font>rs do not have the <font color="blue">capacity</font> or <font color="blue">capability</font> to <font color="blue">manufacture</font>     our  products  <font color="blue">according</font> to our schedule and <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>Also, raw     materials that may be required to <font color="blue">manufacture</font> any products we develop may     only be <font color="blue">available from</font> a limited number of suppliers</td>
    </tr>
    <tr>
      <td>If we have promised     delivery of a new product and are unable to meet the <font color="blue">delivery requirement</font>     due  to  <font color="blue">manufacturing</font> <font color="blue"><font color="blue">difficult</font>ies</font>, our <font color="blue">development</font> programs would be     delayed, and we may have to <font color="blue">expend <font color="blue">additional</font> sums</font> in order to ensure that     <font color="blue">manufacturing</font> <font color="blue">capacity</font> is available when we need it even if we do not use     all of the <font color="blue">manufacturing</font> <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>This expense would <font color="blue"><font color="blue">adversely</font> affect</font> our     operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>of <font color="blue">pharmaceutical</font> products often encounter     <font color="blue"><font color="blue">difficult</font>ies</font> in production, <font color="blue">especially</font> in scaling up initial production</td>
    </tr>
    <tr>
      <td>These  problems include <font color="blue"><font color="blue">difficult</font>ies</font> with production costs and yields,     <font color="blue">quality control</font> and assurance and shortages of qualified personnel, as well     <font color="blue">as compliance with strictly enforced federal</font>, state and foreign <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font>rs we <font color="blue">choose may</font> not perform as agreed or <font color="blue">may terminate</font> their     <font color="blue">agreement</font>s with us</td>
    </tr>
    <tr>
      <td>Foreign <font color="blue">manufacturing</font> <font color="blue">approval process</font>es typically     include  all of the <font color="blue">risks <font color="blue">associated with</font></font> the FDA <font color="blue">approval process</font> for     <font color="blue">manufacturing</font> and may also include <font color="blue"><font color="blue">additional</font> risks</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may incur <font color="blue"><font color="blue">additional</font> expense</font></font> in order to market our <font color="blue"><font color="blue">drug product</font>s</font></td>
    </tr>
    <tr>
      <td>We do not have experience marketing <font color="blue"><font color="blue">drug product</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font><font color="blue">approves one</font>     of our <font color="blue"><font color="blue">drug product</font>s</font> to go to market, we would have to <font color="blue">employ <font color="blue">additional</font></font>     personnel or engage another party to market our <font color="blue"><font color="blue">drug product</font>s</font>, which would     be an <font color="blue"><font color="blue">additional</font> expense</font> to us</td>
    </tr>
    <tr>
      <td>We might not be able to <font color="blue">commercialize</font> our drug <font color="blue">candidates</font> <font color="blue">successfully</font>, and     we may spend <font color="blue">significant</font> time and <font color="blue">money attempting</font> to do so</td>
    </tr>
    <tr>
      <td>DFC, our lead CCR2 <font color="blue">antagonist licensed</font> to Pfizer, and our lead sheddase     inhibitor are our only three drug <font color="blue">candidates</font> in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We, or our     <font color="blue"><font color="blue">collaborator</font>s</font> or licensees, may decide to <font color="blue">discontinue</font> <font color="blue">development</font> of any or     all of our drug <font color="blue">candidates</font> at any time for commercial, scientific or other     reasons</td>
    </tr>
    <tr>
      <td>If a product is developed, but is not marketed, we may have spent     <font color="blue">significant</font> amounts of time and money on it, which would <font color="blue"><font color="blue">adversely</font> affect</font>     our operating results and financial condition</td>
    </tr>
    <tr>
      <td>Even if DFC, or another drug     candidate that we develop, receives <font color="blue">regulatory</font> approval, we may decide not     to <font color="blue">commercialize</font> it if we determine that <font color="blue">commercialization</font> of that product     would  require  more money and time than we are willing to invest</td>
    </tr>
    <tr>
      <td>For     example,  drugs  that  receive approval are subject to post-<font color="blue">regulatory</font>     surveillance and may have to be <font color="blue">withdrawn from</font> the market if <font color="blue">previously</font>     unknown side effects occur</td>
    </tr>
    <tr>
      <td>At this point, the <font color="blue">regulatory</font> agencies may     require <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font> or testing</td>
    </tr>
    <tr>
      <td>Once a drug is marketed, if     it causes side effects, the <font color="blue">drug product</font> may be recalled or may be subject     to re<font color="blue">formulation</font>, <font color="blue">additional</font> studies, changes in labeling, warnings to the     public  and  negative  publicity</td>
    </tr>
    <tr>
      <td>As a result, we may not continue to     <font color="blue">commercialize</font> a product even though it has obtained <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>Further, we may decide not to continue to <font color="blue">commercialize</font> a product if the     market does not accept the product because it is <font color="blue">too expensive</font> and third     <font color="blue">parties such as</font> insurance companies or Medicare have not approved it for     substantial <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Actions of <font color="blue">government</font>al <font color="blue">authorities</font> and other     <font color="blue">groups could</font> result in <font color="blue">lower prices</font> for <font color="blue">certain drugs</font>, including drugs that     address  HIV  infection</td>
    </tr>
    <tr>
      <td>In addition, we may decide not to continue to     <font color="blue">commercialize</font> a product if another <font color="blue">product comes on</font> the market that is as     <font color="blue">effective</font> but has fewer side effects</td>
    </tr>
    <tr>
      <td>There is also a risk that <font color="blue">competitor</font>s     may develop similar or superior products or have <font color="blue"><font color="blue">proprietary</font> rights</font> that     <font color="blue">preclude us from ultimately marketing</font> our products</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       Our ability to <font color="blue">generate revenues will</font> be diminished if we are unable to     obtain acceptable prices or an <font color="blue">adequate level</font> of <font color="blue">reimbursement</font> from payors     of <font color="blue">healthcare costs</font></td>
    </tr>
    <tr>
      <td>The  continuing  efforts of <font color="blue">government</font> and insurance companies, health     <font color="blue">maintenance organizations</font>, or HMOs, and other payors of <font color="blue">healthcare costs</font> to     contain or <font color="blue">reduce costs</font> of <font color="blue"><font color="blue">health care</font> may affect</font> our <font color="blue">future revenues</font> and     <font color="blue">profitability</font>, and the <font color="blue">future revenues</font> and <font color="blue">profitability</font> of our potential     customers,  suppliers  and  <font color="blue">collaborative</font>  or <font color="blue">license partners</font> and the     <font color="blue">availability</font> of capital</td>
    </tr>
    <tr>
      <td>For example, in certain foreign markets, pricing or     <font color="blue">profitability</font> of <font color="blue">prescription</font> <font color="blue">pharmaceutical</font>s is subject to <font color="blue">government</font>     control</td>
    </tr>
    <tr>
      <td>In the United States, <font color="blue">given recent federal</font> and state <font color="blue">government</font>     <font color="blue">initiatives directed at lowering</font> the total cost of <font color="blue">health care</font>, the US     Congress and state <font color="blue">legislatures</font> will likely continue to focus on <font color="blue">health care</font>     reform, the cost of <font color="blue">prescription</font> <font color="blue">pharmaceutical</font>s and on the reform of the     Medicare and Medicaid systems</td>
    </tr>
    <tr>
      <td>While we <font color="blue">cannot predict whether</font> any such     <font color="blue">legislative</font> or <font color="blue">regulatory</font> proposals will be adopted, the <font color="blue">announcement</font> or     adoption of these <font color="blue">proposals could reduce</font> the price that we or any of our     <font color="blue"><font color="blue">collaborator</font>s</font> or licensees receive for any products in the future</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our products <font color="blue">successfully</font> will depend in part     on the extent to which appropriate <font color="blue">reimbursement</font> levels for the cost of our     products and related treatment are obtained by <font color="blue">government</font>al <font color="blue">authorities</font>,     <font color="blue">private health insurers</font> and other organizations, such as HMOs</td>
    </tr>
    <tr>
      <td>Third-party     payors are <font color="blue">increasingly challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font>     and services</td>
    </tr>
    <tr>
      <td>Also, the trend toward managed <font color="blue">health care</font> in the United     States and the <font color="blue">concurrent growth</font> of <font color="blue">organizations such as</font> HMOs, <font color="blue">which could</font>     control or <font color="blue">significant</font>ly influence the purchase of <font color="blue"><font color="blue">health care</font> services</font> and     products, as well as <font color="blue">legislative</font> proposals to <font color="blue">reform <font color="blue">health care</font></font> or reduce     <font color="blue">government</font>  insurance  programs, may all result in <font color="blue">lower prices</font> for or     rejection of our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">cost containment measures</font> that <font color="blue">health care</font>     payors and providers are <font color="blue">instituting</font> and the effect of any <font color="blue">health care</font>     reform  could  <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our ability to generate     revenues</td>
    </tr>
    <tr>
      <td>As  our <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font> <font color="blue">operations</font> are <font color="blue">conducted at</font> our     <font color="blue">headquarters</font> in Wilmington, Delaware, the loss of access to this <font color="blue">facility</font>     would <font color="blue">negatively</font> impact our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">facility</font> in Wilmington, Delaware is our <font color="blue">headquarters</font> and is also where     we conduct all of our <font color="blue">drug <font color="blue">discovery</font></font> <font color="blue">operations</font> and research and <font color="blue">development</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">lease contains provisions</font> that provide for its early     <font color="blue"><font color="blue">termination</font> upon</font> the occurrence of <font color="blue">certain events</font> of default or upon a     change of control</td>
    </tr>
    <tr>
      <td>Further, our <font color="blue">headquarters</font> <font color="blue">facility</font> is located in a large     research and <font color="blue">development</font> complex that may be <font color="blue">temporarily</font> or <font color="blue">permanently</font>     shutdown if <font color="blue">certain environmental</font> or other <font color="blue">hazardous</font> <font color="blue">conditions</font> were to     occur within the complex</td>
    </tr>
    <tr>
      <td>In addition, actions of <font color="blue">activists opposed</font> to     aspects  of <font color="blue">pharmaceutical</font> research may disrupt our <font color="blue">experiments</font> or our     ability to access or use our <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>The loss of access to or use of our     Wilmington, Delaware, <font color="blue">facility</font>, either on a temporary or <font color="blue">permanent basis</font>, or     early  <font color="blue">termination</font> of our <font color="blue">lease would</font> result in an <font color="blue">interruption</font> of our     business and, consequently, would <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">advancement</font> of our     <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font> programs and our overall business</td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">depend on</font> <font color="blue">key employees</font></font> in a <font color="blue">competitive market</font> for <font color="blue">skilled personnel</font>,     and the loss of the services of any of our <font color="blue"><font color="blue">key employees</font> would affect</font> our     ability to expand our <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font> programs and achieve     our <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>We  are  highly  <font color="blue">dependent on</font> the <font color="blue">principal members</font> of our <font color="blue">management</font>,     <font color="blue">operations</font> and <font color="blue">scientific staff</font></td>
    </tr>
    <tr>
      <td>We experience <font color="blue">intense competition</font> for     qualified  personnel</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">future success also depends</font> in part on the     <font color="blue">continued service</font> of our executive <font color="blue">management</font> team, key scientific and     <font color="blue">management</font> personnel and our ability to recruit, train and retain essential     scientific  personnel for our <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font> programs,     including those who will be responsible for overseeing our preclinical     testing  and  clinical  trials  as  well  as  for the <font color="blue">establishment</font> of     <font color="blue">collaboration</font>s with other companies</td>
    </tr>
    <tr>
      <td>If we lose the services of any of these     people,  our  research  and  product  <font color="blue">development</font> goals, including the     <font color="blue">identification</font> and <font color="blue">establishment</font> of key       21     ______________________________________________________________________       <font color="blue">collaboration</font>s,  <font color="blue">operations</font>  and <font color="blue">marketing efforts could</font> be delayed or     curtailed</td>
    </tr>
    <tr>
      <td>We  do  not  maintain “key person” <font color="blue">insurance on</font> any of our     employees</td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue">integrating companies</font> we acquire, which may     harm our <font color="blue">operations</font> and financial results</td>
    </tr>
    <tr>
      <td>As part of our business strategy, we have in the past and may in the future     acquire  assets,  <font color="blue">technologies</font>,  compounds  and  <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Our past     <font color="blue">acquisition</font>s, such as the <font color="blue">acquisition</font> of Maxia have involved, and our future     <font color="blue">acquisition</font>s may involve, risks such as the following:       ·       we may be exposed to <font color="blue">unknown <font color="blue">liabilities</font></font> of acquired companies;       ·        our  <font color="blue">acquisition</font>  and <font color="blue">integration costs may</font> be <font color="blue">higher than</font> we     anticipated and may cause our quarterly and annual operating results to     fluctuate;       ·        we  may experience <font color="blue"><font color="blue">difficult</font>y</font> and expense in <font color="blue">assimilating</font> the     <font color="blue">operations</font> and personnel of the acquired <font color="blue">businesses</font>, disrupting our business     and diverting our <font color="blue">management</font>’s time and attention;       ·        we may be unable to integrate or complete the <font color="blue">development</font> and     <font color="blue">application</font> of acquired <font color="blue">technology</font>, compounds or drug <font color="blue">candidates</font>;       ·       we may experience <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue">establishing</font> and maintaining     uniform standards, controls, procedures and policies;       ·       our <font color="blue">relationship</font>s with key customers, suppliers, or <font color="blue">collaborative</font> or     <font color="blue">license partners</font> of acquired <font color="blue">businesses</font> may be impaired, due to changes in     <font color="blue">management</font> and ownership of the acquired <font color="blue">businesses</font>;       ·       we may be unable to retain <font color="blue">key employees</font> of the acquired <font color="blue">businesses</font>;       ·       we <font color="blue">may incur amortization</font> or <font color="blue"><font color="blue">impairment</font> expenses</font> if an <font color="blue">acquisition</font>     results in <font color="blue">significant</font> goodwill or other <font color="blue">intangible assets</font>; or       ·       our <font color="blue">stockholders</font> may be diluted if we pay for the <font color="blue">acquisition</font> with     <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>In addition, if we acquire <font color="blue">additional</font> <font color="blue">businesses</font> that are not located near     our new <font color="blue">headquarters</font>, we may experience more <font color="blue"><font color="blue">difficult</font>y</font> integrating and     managing the acquired <font color="blue">businesses</font>’ <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If  product  <font color="blue">liability</font>  lawsuits are <font color="blue">brought <font color="blue">against us</font></font>, we could face     substantial <font color="blue">liabilities</font> and may be required to limit <font color="blue">commercialization</font> of     our products and our results of <font color="blue">operations</font> could be harmed</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">clinical trial</font>s</font> and marketing of <font color="blue">medical products</font> that are intended for     <font color="blue">human use entails</font> an <font color="blue">inherent risk</font> of product <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>If any product that     we or any of our <font color="blue"><font color="blue">collaborator</font>s</font> or licensees develops causes or is alleged to     cause  injury  or  is  found  to be unsuitable during <font color="blue"><font color="blue">clinical trial</font>s</font>,     <font color="blue">manufacturing</font> or sale, we may be held liable</td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">successfully</font>     defend ourselves against product <font color="blue">liability</font> claims, we may incur substantial     <font color="blue">liabilities</font>, including substantial damages to be paid to the plaintiffs and     legal  costs,  or we may be required to limit <font color="blue">commercialization</font> of our     products</td>
    </tr>
    <tr>
      <td>Although we currently carry a product <font color="blue">liability</font> insurance policy     that <font color="blue">provides coverage</font> for <font color="blue">liabilities</font> arising from our <font color="blue"><font color="blue">clinical trial</font>s</font>, it     may not <font color="blue">fully cover</font> our potential <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>In addition, we may determine     that we <font color="blue">should increase</font> our <font color="blue">coverage upon</font> the undertaking of new clinical     trials, and this <font color="blue">insurance may</font> be <font color="blue">prohibitively expensive</font> to us or our     <font color="blue"><font color="blue">collaborator</font>s</font>  or  licensees  and  may  not  <font color="blue">fully cover</font> our potential     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to obtain sufficient product <font color="blue">liability</font> insurance     at an acceptable cost to protect against <font color="blue">potential product</font> <font color="blue">liability</font> claims     <font color="blue">could prevent</font> or inhibit the <font color="blue">commercialization</font> of <font color="blue">pharmaceutical</font> products we     develop,  alone  or  with our <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>Additionally, any product     <font color="blue">liability</font> lawsuit could cause injury to our reputation, recall of products,     <font color="blue">participants</font> to withdraw from <font color="blue"><font color="blue">clinical trial</font>s</font>, and <font color="blue">potential <font color="blue"><font color="blue">collaborator</font>s</font></font>     or licensees to seek other partners, any of <font color="blue">which could</font> impact our results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       Because our <font color="blue">activities</font> involve the use of <font color="blue"><font color="blue">hazardous</font> materials</font>, we may be     subject to claims relating to improper handling, storage or disposal of     these materials that could be time consuming and costly</td>
    </tr>
    <tr>
      <td>We  are  subject  to various environmental, health and safety laws and     <font color="blue">regulations</font> governing, among other things, the use, handling, storage and     disposal of <font color="blue">regulated substances</font> and the health and safety of our employees</td>
    </tr>
    <tr>
      <td>Our  research  and <font color="blue">development</font> processes involve the <font color="blue">controlled use</font> of     <font color="blue">hazardous</font> and <font color="blue">radioactive materials</font> and <font color="blue">biological waste</font> resulting in the     production of <font color="blue">hazardous</font> waste products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot completely eliminate</font> the     risk of <font color="blue">accidental <font color="blue">contamination</font></font> or discharge and any <font color="blue">resultant injury from</font>     these materials</td>
    </tr>
    <tr>
      <td>If any injury or <font color="blue">contamination</font> results from our use or the     use by our <font color="blue"><font color="blue">collaborator</font>s</font> or licensees of these materials, we may be sued and     our  <font color="blue">liability</font> may exceed our <font color="blue">insurance coverage</font> and our <font color="blue">total assets</font></td>
    </tr>
    <tr>
      <td>Further, we may be required to indemnify our <font color="blue"><font color="blue">collaborator</font>s</font> or licensees     against all damages and other <font color="blue">liabilities</font> arising out of our <font color="blue">development</font>     <font color="blue">activities</font> or products produced in <font color="blue"><font color="blue">connection</font> with</font> these <font color="blue">collaboration</font>s or     licenses</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with the <font color="blue">applicable environmental</font> and <font color="blue">workplace laws</font>     and <font color="blue">regulations</font> is expensive</td>
    </tr>
    <tr>
      <td>Future changes to environmental, health,     workplace and <font color="blue">safety laws could</font> cause us to incur <font color="blue"><font color="blue">additional</font> expense</font> or may     restrict our <font color="blue">operations</font> or impair our research, <font color="blue">development</font> and production     efforts</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       RISKS RELATING TO OUR FINANCIAL RESULTS       We expect to <font color="blue">incur losses</font> in the future and we may not achieve or maintain     <font color="blue">profitability</font> in the future</td>
    </tr>
    <tr>
      <td>We had <font color="blue">net losses from inception</font> in 1991 through 1996 and in 1999 through     2005</td>
    </tr>
    <tr>
      <td>Because of those losses, we had an <font color="blue">accumulated</font> deficit of dlra839dtta3     million as <font color="blue">of December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We <font color="blue">will continue</font> to spend <font color="blue">significant</font>     <font color="blue">amounts on</font> our efforts to discover and develop drugs</td>
    </tr>
    <tr>
      <td>As a result, we expect     to continue to <font color="blue">incur losses</font> in 2006 and in <font color="blue">future periods as well</font></td>
    </tr>
    <tr>
      <td>We anticipate that our <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue"><font color="blue">development</font> efforts</font> will increase     as we focus on the studies, including <font color="blue">preclinical test</font>s and <font color="blue"><font color="blue">clinical trial</font>s</font>     prior to seeking <font color="blue">regulatory</font> approval, that are required before we can sell a     <font color="blue">drug product</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of <font color="blue"><font color="blue">drug product</font>s</font> will require us to spend     <font color="blue">significant</font> funds on research, <font color="blue">development</font>, testing, obtaining <font color="blue">regulatory</font>     approvals, <font color="blue">manufacturing</font> and marketing</td>
    </tr>
    <tr>
      <td>To date, we do not have any drug     products that have <font color="blue">generated revenues</font> and we <font color="blue">cannot assure</font> you that we will     <font color="blue">generate revenues from</font> the drug <font color="blue">candidates</font> that we license or develop for     <font color="blue">several years</font>, if ever</td>
    </tr>
    <tr>
      <td>We cannot be <font color="blue">certain whether</font> or when we will achieve     <font color="blue">profitability</font> because of the <font color="blue">significant</font> uncertainties relating to our     ability to generate commercially successful <font color="blue"><font color="blue">drug product</font>s</font></td>
    </tr>
    <tr>
      <td>Even if we were     successful  in  obtaining  <font color="blue">regulatory</font>  approvals for <font color="blue">manufacturing</font> and     <font color="blue">commercializing</font> DFC, our <font color="blue">leading drug candidate</font>, or another drug, we expect     that we <font color="blue">will continue</font> to <font color="blue">incur losses</font> if our <font color="blue"><font color="blue">drug product</font>s</font> do not generate     <font color="blue">significant</font> revenues</td>
    </tr>
    <tr>
      <td>If we achieve <font color="blue">profitability</font> we may not be able to     sustain or increase <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We will need <font color="blue">additional</font> capital in the future</td>
    </tr>
    <tr>
      <td>The <font color="blue">capital markets may</font> not     <font color="blue">permit us</font> to raise <font color="blue">additional</font> capital at the time that we require it, which     could  result  in  <font color="blue">limitations</font>  on  our  research  and  <font color="blue">development</font> or     <font color="blue">commercialization</font>  efforts or the loss of certain of our rights in our     <font color="blue">technologies</font> or drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our  future  funding  <font color="blue">requirements</font>  will <font color="blue">depend on</font> many factors and we     anticipate  that  we will need to raise <font color="blue">additional</font> capital to fund our     business plan and research and <font color="blue"><font color="blue">development</font> efforts</font> on a going-forward basis</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>factors that may affect our future funding <font color="blue">requirements</font> include:       ·       any changes in the breadth of our research and <font color="blue">development</font> programs;       ·       the results of research and <font color="blue">development</font>, <font color="blue"><font color="blue">preclinical test</font>ing</font> and     <font color="blue"><font color="blue">clinical trial</font>s</font> conducted by us or our future <font color="blue">collaborative</font> partners or     licensees, if any;       ·        the  <font color="blue">acquisition</font>  or licensing of <font color="blue">businesses</font>, <font color="blue">technologies</font> or     compounds, if any;       ·       our ability to maintain and establish new corporate <font color="blue">relationship</font>s     and research <font color="blue">collaboration</font>s;       ·       <font color="blue">competing technological</font> and market <font color="blue">development</font>s;       ·       the amount of <font color="blue">revenues generated from</font> our business <font color="blue">activities</font>, if     any;       ·       the time and <font color="blue">costs involved</font> in filing, prosecuting, defending and     <font color="blue">enforcing patent</font> and <font color="blue">intellectual</font> property claims;       ·       the receipt of <font color="blue">contingent</font> licensing or <font color="blue">milestone fees</font> or royalties     on  <font color="blue">product sales from</font> our current or future <font color="blue">collaborative</font> and license     <font color="blue">arrangements</font>, if established; and       ·       the timing of <font color="blue">regulatory</font> approvals, if any</td>
    </tr>
    <tr>
      <td>If we require <font color="blue">additional</font> capital at a time when <font color="blue">investment</font> in <font color="blue">companies such</font>     as  ours,  or in the marketplace generally, is limited due to the then     prevailing  market  or other <font color="blue">conditions</font>, we may have to scale back our     <font color="blue">operations</font>, eliminate one or more of our research or <font color="blue">development</font> programs,     or  attempt  to  obtain  funds  by  entering  into an <font color="blue">agreement</font> with a     <font color="blue">collaborative</font> partner that would result in terms that are not favorable to     us or <font color="blue">relinquishing</font> our rights in certain of our <font color="blue">proprietary</font> <font color="blue">technologies</font> or     drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________       If we are unable to <font color="blue">raise funds at</font> the time that we desire or at any time     <font color="blue">thereafter on</font> acceptable terms, we may not be able to continue to develop     our potential <font color="blue"><font color="blue">drug product</font>s</font></td>
    </tr>
    <tr>
      <td>The sale of equity or <font color="blue">additional</font> convertible     <font color="blue">debt securities</font> in the <font color="blue">future would</font> be dilutive to our <font color="blue">stockholders</font>, and     debt financing <font color="blue">arrangements</font> may require us to <font color="blue">pledge certain assets</font> or enter     <font color="blue">into covenants</font> that <font color="blue">could restrict</font> our <font color="blue">operations</font> or our ability to incur     <font color="blue">further indebtedness</font></td>
    </tr>
    <tr>
      <td>Future milestone and <font color="blue">royalty <font color="blue">payments from</font></font> our gene and genomics-related     <font color="blue">intellectual</font> property may not contribute <font color="blue">significant</font>ly to revenues for     <font color="blue">several years</font>, and may never result in revenues</td>
    </tr>
    <tr>
      <td>Part of our strategy was to license to our database customers and to other     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies our know-how and <font color="blue">patent rights</font>     <font color="blue">associated with</font> the information we have generated in the creation of our     <font color="blue"><font color="blue">proprietary</font> databases</font>, for use in the <font color="blue">discovery</font> and <font color="blue">development</font> of potential     <font color="blue">pharmaceutical</font>, diagnostic or other products</td>
    </tr>
    <tr>
      <td>Any <font color="blue">potential product</font> that is     the  subject  of  such a <font color="blue">license will</font> require <font color="blue">several years</font> of further     <font color="blue">development</font>,   clinical   trials   and   <font color="blue">regulatory</font>   approval  before     <font color="blue">commercialization</font>, all of which is beyond our control, and <font color="blue">possibly beyond</font>     the control of our licensee</td>
    </tr>
    <tr>
      <td>These <font color="blue">licensees may</font> not develop the potential     product if they do not devote the <font color="blue">necessary</font> resources or decide that they do     not want to expend the resources to do the <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">necessary</font> to     obtain the <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>Therefore, milestone or royalty     <font color="blue">payments from</font> these <font color="blue">licenses may</font> not contribute to our revenues for several     years,  if at all</td>
    </tr>
    <tr>
      <td>We have decided to <font color="blue">discontinue</font> some of our gene and     genomics-related patent <font color="blue">prosecution</font> and maintenance, and may in the future     decide  to  <font color="blue">discontinue</font>  <font color="blue">additional</font>  gene  and genomics-related patent     <font color="blue">prosecution</font>  and maintenance, <font color="blue">which could</font> limit our ability to receive     license-based revenues from our gene and genomics-related <font color="blue">patent portfolio</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue"><font color="blue">investment</font>s</font> may decline</font> in value and our <font color="blue">losses may increase</font></td>
    </tr>
    <tr>
      <td>We  have  made and may in the future make <font color="blue"><font color="blue">investment</font>s</font> in entities that     <font color="blue">complement</font> our business</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">investment</font>s</font> may:       ·       often be made in <font color="blue">securities lacking</font> a <font color="blue">public trading market</font> or     subject to trading restrictions, either of <font color="blue">which increases</font> our risk and     reduces the liquidity of our <font color="blue">investment</font>;       ·       require us to <font color="blue">record losses</font> and expenses related to our ownership     interest;       ·       require us to record <font color="blue">acquisition</font>-related charges, such as in-process     research and <font color="blue">development</font>;       ·       require us to <font color="blue">record charges</font> related to the <font color="blue">impairment</font> in the value     of the <font color="blue">securities underlying</font> our <font color="blue">investment</font>; and       ·       require us to <font color="blue">invest greater amounts than</font> anticipated or to devote     substantial <font color="blue">management</font> time to the <font color="blue">management</font> of research and <font color="blue">development</font>     <font color="blue">relationship</font>s or other <font color="blue">relationship</font>s</td>
    </tr>
    <tr>
      <td>The <font color="blue">market values</font> of many of these <font color="blue"><font color="blue">investment</font>s</font> can fluctuate <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>We evaluate our long-term <font color="blue"><font color="blue">investment</font>s</font> for <font color="blue">impairment</font> of their value on a     <font color="blue">quarterly basis</font></td>
    </tr>
    <tr>
      <td>The value of our <font color="blue"><font color="blue">investment</font>s</font> in <font color="blue">private companies</font> can     fluctuate <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>In past periods, market <font color="blue">conditions</font> have caused us     to  write-down the value of our private company <font color="blue"><font color="blue">investment</font>s</font>, sometimes     <font color="blue">substantially</font>, and market <font color="blue">conditions</font> may cause us to write down <font color="blue">additional</font>     amounts</td>
    </tr>
    <tr>
      <td>In addition, we have in the <font color="blue">past written down</font> the value of our debt     <font color="blue"><font color="blue">investment</font>s</font> in companies experiencing financial <font color="blue"><font color="blue">difficult</font>ies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Impairment     </font>could result in <font color="blue">future charges</font> to our earnings</td>
    </tr>
    <tr>
      <td><font color="blue">Decreases </font>in the value of     our strategic <font color="blue"><font color="blue">investment</font>s</font> may cause our losses to increase</td>
    </tr>
    <tr>
      <td>We have a large amount of debt and our debt service <font color="blue">obligations</font> may prevent     us from taking actions that we <font color="blue">would otherwise</font> consider to be in our best     interests</td>
    </tr>
    <tr>
      <td>As <font color="blue">of December </font>31, 2005, we had <font color="blue">total consolidated debt</font> of dlra341dtta9 million     and <font color="blue">stockholders</font>’ deficit of dlra19dtta4 million</td>
    </tr>
    <tr>
      <td>The <font color="blue">indentures pursuant</font> to which     our <font color="blue"><font color="blue">outstanding convertible</font> subordinated</font> notes were       25     ______________________________________________________________________       issued do not limit the issuance of <font color="blue">additional</font> indebtedness</td>
    </tr>
    <tr>
      <td>Our substantial     leverage  could  have <font color="blue">significant</font> negative consequences for our future     <font color="blue">operations</font>, including:       ·        increasing  our <font color="blue">vulnerability</font> to general adverse economic and     industry <font color="blue">conditions</font>;       ·       limiting our ability to obtain <font color="blue">additional</font> financing for working     capital, capital and research and <font color="blue">development</font> <font color="blue">expenditures</font>, and general     <font color="blue">corporate purposes</font>;       ·       requiring the <font color="blue">dedication</font> of a substantial portion of our expected     <font color="blue">cash flow</font> or our <font color="blue">existing cash</font> to service our indebtedness, thereby reducing     the amount of our <font color="blue">cash available</font> for other purposes, including working     capital, capital <font color="blue">expenditures</font> and research and <font color="blue">development</font> <font color="blue">expenditures</font>;       ·       limiting our <font color="blue">flexibility</font> in planning for, or reacting to, changes in     our business and the industry in which we compete; or       ·       <font color="blue">placing us at</font> a <font color="blue">possible competitive disadvantage compared</font> to less     leveraged <font color="blue">competitor</font>s and <font color="blue">competitor</font>s that have <font color="blue">better access</font> to capital     resources</td>
    </tr>
    <tr>
      <td>In the past five years, we have had negative <font color="blue">cash flow</font> from <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">likely will</font> not generate sufficient <font color="blue">cash flow</font> from our <font color="blue">operations</font> in the     future to <font color="blue">enable us</font> to meet our anticipated fixed charges, including our     debt  service <font color="blue">requirements</font> with respect to our <font color="blue">outstanding convertible</font>     subordinated  notes</td>
    </tr>
    <tr>
      <td>As <font color="blue">of December </font>31, 2005, dlra91dtta6 million aggregate     <font color="blue">principal amount</font> of our 5dtta5prca convertible subordinated notes due 2007 were     outstanding</td>
    </tr>
    <tr>
      <td>Our annual interest payments for the 5dtta5prca notes through 2006,     assuming  none  of these notes are converted, redeemed, repurchased or     exchanged, are dlra5dtta0 million, and an <font color="blue">additional</font> dlra2dtta5 million in interest is     payable in 2007</td>
    </tr>
    <tr>
      <td>As <font color="blue">of December </font>31, 2005, dlra250 million aggregate principal     amount  of  our  31¤2prca  convertible  subordinated  notes due 2011 were     outstanding</td>
    </tr>
    <tr>
      <td>Our annual interest payments for the 31¤2prca notes through 2010,     assuming  none  of these notes are converted, redeemed, repurchased or     exchanged, are dlra8dtta8 million, and an <font color="blue">additional</font> dlra4dtta4 million in interest is     payable in 2011</td>
    </tr>
    <tr>
      <td>We intend to fulfill our debt service <font color="blue">obligations</font> from our     <font color="blue">existing cash</font> and <font color="blue">marketable securities</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">generate cash</font>     from our <font color="blue">operations</font> or raise <font color="blue">additional</font> cash through financings sufficient     to meet these <font color="blue">obligations</font>, we will need to use <font color="blue">existing cash</font> or liquidate     <font color="blue">marketable securities</font> in order to fund these <font color="blue">obligations</font>, which may delay or     curtail our research, <font color="blue">development</font> and <font color="blue">commercialization</font> programs</td>
    </tr>
    <tr>
      <td>RISKS RELATING TO INTELLECTUAL PROPERTY AND LEGAL MATTERS       We are involved in patent <font color="blue">litigation</font>, which, if not <font color="blue">resolved favorably</font>,     could require us to pay damages</td>
    </tr>
    <tr>
      <td>In  October 2001, <font color="blue"><font color="blue">Invitrogen </font>Corporation </font>filed an <font color="blue">action <font color="blue">against us</font></font> in     <font color="blue">federal district court</font> for the District of Delaware, alleging <font color="blue">infringement</font>     of  three  patents</td>
    </tr>
    <tr>
      <td>The <font color="blue">complaint seeks unspecified money damages</font> and     <font color="blue">injunctive relief</font></td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2001, we filed our answer to Invitrogen’s     patent  <font color="blue">infringement</font>  claims, and asserted <font color="blue">seven <font color="blue"><font color="blue">counterclaim</font>s</font> against</font>     Invitrogen, <font color="blue">seeking declaratory relief with respect</font> to the <font color="blue">patents at issue</font>,     implied license, estoppel, laches and <font color="blue">patent misuse</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">also seeking</font> our     fees, costs and expenses</td>
    </tr>
    <tr>
      <td><font color="blue">Invitrogen </font>filed its answer to our <font color="blue"><font color="blue">counterclaim</font>s</font>     in  January 2002</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2003, we added a <font color="blue">counterclaim</font> for unfair     business practices</td>
    </tr>
    <tr>
      <td>Our <font color="blue">defenses against</font> the <font color="blue">suit brought by</font> <font color="blue">Invitrogen </font>may be <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>At     this time, we <font color="blue">cannot reasonably</font> estimate the <font color="blue">possible range</font> of any loss or     damages resulting from this suit due to <font color="blue">uncertainty</font> regarding the ultimate     outcome</td>
    </tr>
    <tr>
      <td>If the case goes forward, we expect that the <font color="blue">Invitrogen </font><font color="blue">litigation</font>     will  result  in <font color="blue">future legal</font> and other costs to us, regardless of the     outcome, <font color="blue">which could</font> be substantial</td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________       If we are subject to <font color="blue">additional</font> <font color="blue">arbitration</font>, <font color="blue">litigation</font> and <font color="blue">infringement</font>     claims, they could be costly and disrupt our <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font>     efforts</td>
    </tr>
    <tr>
      <td>The  <font color="blue">technology</font> that we use to make and develop our <font color="blue"><font color="blue">drug product</font>s</font>, the     <font color="blue">technology</font> that we <font color="blue">incorporate</font> in our products, and the products we are     developing  may be subject to claims that they infringe the patents or     <font color="blue">proprietary</font>  rights  of  others</td>
    </tr>
    <tr>
      <td>The success of our <font color="blue">drug <font color="blue">discovery</font></font> and     <font color="blue">development</font>  efforts  will  also  <font color="blue">depend on</font> our ability to develop new     compounds, drugs and <font color="blue">technologies</font> without infringing or <font color="blue">misappropriating</font> the     <font color="blue">proprietary</font>  rights  of  others</td>
    </tr>
    <tr>
      <td>We  are  aware of patents and patent     <font color="blue"><font color="blue">application</font>s</font>  filed in <font color="blue">certain countries</font> claiming certain <font color="blue">intellectual</font>     property  relating  to  CCR5</td>
    </tr>
    <tr>
      <td>While  the  validity of issued patents,     <font color="blue">patentability</font> of pending patent <font color="blue"><font color="blue">application</font>s</font> and <font color="blue">applicability</font> of any of     them to our programs are uncertain, if any of these patents are asserted     <font color="blue">against us</font>, our ability to <font color="blue">commercialize</font> our <font color="blue">products could</font> be harmed</td>
    </tr>
    <tr>
      <td>From time to time we may receive notices from <font color="blue">third parties</font> alleging patent,     trademark, or copyright <font color="blue">infringement</font>, claims regarding <font color="blue"><font color="blue">trade secret</font>s</font> or     other contract claims</td>
    </tr>
    <tr>
      <td>Receipt of these notices could result in <font color="blue">significant</font>     costs as a result of the diversion of the attention of <font color="blue">management</font> from our     <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue"><font color="blue">development</font> efforts</font></td>
    </tr>
    <tr>
      <td>Except for Invitrogen, no third     party has a current filed <font color="blue">patent laws</font>uit or <font color="blue">arbitration</font> <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>If a     successful  claim were <font color="blue">brought <font color="blue">against us</font></font>, we would have to attempt to     license the <font color="blue">technology</font> from the claimant or to spend time and money to     <font color="blue">design around</font> the <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">such license</font> of the <font color="blue">technology</font> may not be     <font color="blue">available at reasonable terms</font>, or at all</td>
    </tr>
    <tr>
      <td>We may, however, be involved in <font color="blue">future lawsuits</font> or other <font color="blue">legal proceedings</font>     alleging  patent <font color="blue">infringement</font> or other <font color="blue">intellectual</font> property rights or     <font color="blue">contract violations</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">litigation</font> or other <font color="blue">legal proceedings</font> may     be <font color="blue">necessary</font> to:       ·       assert claims of <font color="blue">infringement</font>;       ·       enforce our patents or <font color="blue">trademarks</font>;       ·       protect our <font color="blue"><font color="blue">trade secret</font>s</font> or know-how; or       ·       determine the enforceability, scope and validity of the <font color="blue">proprietary</font>     rights of others</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">unsuccessful</font> in defending or pursuing these lawsuits or claims</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of the outcome, <font color="blue">litigation</font> can be very costly and can divert     <font color="blue">management</font>’s efforts</td>
    </tr>
    <tr>
      <td>An adverse de<font color="blue">termination</font> may subject us to <font color="blue">significant</font>     <font color="blue">liabilities</font> or require us or our <font color="blue"><font color="blue">collaborator</font>s</font> or licensees to <font color="blue">seek licenses</font>     to other parties’ patents or <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>We or our <font color="blue"><font color="blue">collaborator</font>s</font> or     <font color="blue">licensees may</font> also be restricted or prevented from <font color="blue">manufacturing</font> or selling     a <font color="blue">drug product</font> that we develop</td>
    </tr>
    <tr>
      <td>Further, we or our future <font color="blue"><font color="blue">collaborator</font>s</font> or     <font color="blue">licensees may</font> not be able to obtain any <font color="blue">necessary</font> licenses on acceptable     terms, if at all</td>
    </tr>
    <tr>
      <td>We  may  be  unable  to  <font color="blue">adequately protect</font> or enforce our <font color="blue">proprietary</font>     information, which may result in its <font color="blue"><font color="blue">unauthorized</font> use</font>, a loss of revenue     under a <font color="blue">collaboration</font> <font color="blue">agreement</font> or loss of sales to <font color="blue">generic versions</font> of our     products or <font color="blue">otherwise reduce</font> our ability to compete</td>
    </tr>
    <tr>
      <td>Our business and <font color="blue">competitive position depend</font> in part upon our ability to     protect our <font color="blue">proprietary</font> <font color="blue">technology</font>, including any <font color="blue"><font color="blue">drug product</font>s</font> that we     create</td>
    </tr>
    <tr>
      <td>Despite our efforts to protect this information, <font color="blue">unauthorized</font>     parties  may  attempt  to obtain and use information that we regard as     <font color="blue">proprietary</font></td>
    </tr>
    <tr>
      <td>For example, one of our <font color="blue"><font color="blue">collaborator</font>s</font> may disclose <font color="blue">proprietary</font>     information pertaining to our <font color="blue">drug <font color="blue">discovery</font></font> efforts</td>
    </tr>
    <tr>
      <td>Any <font color="blue">patents issued</font> in     <font color="blue">connection</font>  with our <font color="blue">drug <font color="blue">discovery</font></font> efforts may not be <font color="blue">broad enough</font> to     protect all of the <font color="blue">potential uses</font> of the product</td>
    </tr>
    <tr>
      <td>Additionally,  when we do not control the <font color="blue">prosecution</font>, maintenance and     <font color="blue">enforcement</font> of certain important <font color="blue">intellectual</font> property, such as a drug     compound in-licensed to us, the protection of the <font color="blue">intellectual</font> property     <font color="blue">rights may</font> not be in our hands</td>
    </tr>
    <tr>
      <td>In the case of DFC, we do not control the     <font color="blue">intellectual</font> property rights in-licensed to <font color="blue">us with respect</font> to the compound     and <font color="blue">therefore may</font> be unable to protect       27     ______________________________________________________________________       those rights</td>
    </tr>
    <tr>
      <td>If the entity that controls the <font color="blue">intellectual</font> property rights     related to DFC does not <font color="blue">adequately protect</font> those rights, our <font color="blue">rights may</font> be     impaired, which may impact our ability to develop, market and <font color="blue">commercialize</font>     DFC       For  DFC,  a <font color="blue">composition</font> of matter patent is not available because the     compound is in the <font color="blue">public domain</font></td>
    </tr>
    <tr>
      <td>Therefore, <font color="blue">only <font color="blue">patents covering</font></font> the     “use” and the method of “making” of the product are available</td>
    </tr>
    <tr>
      <td>In general,     <font color="blue">patents covering</font> a new use for a <font color="blue">known compound</font> and methods of making a     <font color="blue">known compound</font> can be more <font color="blue">difficult</font> to <font color="blue">enforce against infringers</font></td>
    </tr>
    <tr>
      <td>Our means of protecting our <font color="blue">proprietary</font> <font color="blue">rights may</font> not be adequate, and our     <font color="blue">competitor</font>s may:       ·                     <font color="blue">independently</font>  develop  <font color="blue">substantially</font> equivalent     <font color="blue">proprietary</font> information, products and <font color="blue">techniques</font>;       ·                    otherwise gain access to our <font color="blue">proprietary</font> information;     or       ·                     design  around <font color="blue">patents issued</font> to us or our other     <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>We pursue a policy of having our employees, consultants and advisors execute     <font color="blue">proprietary</font> information and invention <font color="blue">agreement</font>s when they begin working for     us</td>
    </tr>
    <tr>
      <td>However, these <font color="blue">agreement</font>s may not <font color="blue">provide meaningful protection</font> for our     <font color="blue"><font color="blue">trade secret</font>s</font> or other <font color="blue">proprietary</font> information in the event of <font color="blue">unauthorized</font>     use  or  <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>If  we  fail to maintain <font color="blue">trade secret</font> and patent     protection, our potential, <font color="blue">future revenues</font> may be decreased</td>
    </tr>
    <tr>
      <td>If the <font color="blue">effective</font> term of our patents is decreased due to changes in the     United  States  <font color="blue">patent laws</font> or if we need to refile some of our patent     <font color="blue"><font color="blue">application</font>s</font>, the value of our <font color="blue">patent portfolio</font> and the revenues we derive     from it may be decreased</td>
    </tr>
    <tr>
      <td>The value of our <font color="blue">patents depends</font> in part on their duration</td>
    </tr>
    <tr>
      <td>A <font color="blue">shorter period</font>     of <font color="blue"><font color="blue">patent protection</font> could lessen</font> the value of our <font color="blue">rights under</font> any patents     that we obtain and may decrease the revenues we <font color="blue">derive from</font> our patents</td>
    </tr>
    <tr>
      <td>The     <font color="blue">United States </font><font color="blue">patent laws</font> were amended in 1995 to change the term of patent     protection from 17 years from patent issuance to 20 years from the earliest     <font color="blue">effective</font> filing date of the <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>Because the time from filing to     issuance  of  <font color="blue">bio<font color="blue">technology</font></font>  <font color="blue"><font color="blue">application</font>s</font> may be more than three years     depending on the subject matter, a 20-year patent term from the filing date     may result in <font color="blue">substantially</font> shorter <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>Also, we may need to     refile some of our <font color="blue"><font color="blue">application</font>s</font> filed before 1995 that claim large numbers     of genes or other <font color="blue">additional</font> subject matter and, in these situations, the     patent  term  will  be <font color="blue">measured from</font> the date of the <font color="blue">earliest priority</font>     <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">would shorten</font> our period of <font color="blue">patent exclusivity</font> and may     decrease the revenues that we might <font color="blue">derive from</font> the patents</td>
    </tr>
    <tr>
      <td><font color="blue">International </font><font color="blue">patent protection</font> is <font color="blue">particularly uncertain</font> and costly, and if     we are involved in <font color="blue">opposition proceedings</font> in <font color="blue">foreign countries</font>, we may have     to expend substantial sums and <font color="blue">management</font> resources</td>
    </tr>
    <tr>
      <td>Bio<font color="blue">technology</font> and <font color="blue">pharmaceutical</font> patent law outside the <font color="blue">United States </font>is     even more uncertain and <font color="blue">costly than</font> <font color="blue">in the <font color="blue">United States </font></font>and is currently     undergoing review and revision in many countries</td>
    </tr>
    <tr>
      <td>Further, the laws of some     <font color="blue">foreign countries</font> may not protect our <font color="blue">intellectual</font> property rights to the     <font color="blue">same extent as</font> <font color="blue">United States </font>laws</td>
    </tr>
    <tr>
      <td>For example, <font color="blue">certain countries</font> do not     <font color="blue">grant patent</font> claims that are directed to the treatment of humans</td>
    </tr>
    <tr>
      <td>We may     <font color="blue">participate</font> in <font color="blue">opposition proceedings</font> to determine the validity of our     <font color="blue">foreign patents</font> or our <font color="blue">competitor</font>s’ <font color="blue">foreign patents</font>, <font color="blue">which could</font> result in     substantial costs and diversion of our efforts</td>
    </tr>
  </tbody>
</table>